New report published by Ameco Research which offers insights on the global Heparin Sodium market. The global Heparin Sodium market is valued at USD 710 million in 2017 and is expected to reach USD 924 million by the end of 2024, growing at a growth rate of 3.84% between 2017 and 2024.
Global Heparin Sodium Market: Market Driver and Restraint
Heparin sodium is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots.
Global Heparin Sodium Market: Key Takeaways
This report studies the Heparin Sodium market size (value and volume) by players, regions, product types and end industries, history data 2013-2017 and forecast data 2019-2024; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.
Global Heparin Sodium Market: Forecast by Application
Heparin sodium is an anticoagulant (blood thinner) that prevents the formation of blood clots. With the accelerated pace of life and increasing aging population, global morbidity and mortality of cardiovascular and cerebrovascular disease are increased year by year. At present, the world's major consumers are located in Germany, Italy, France, Austria, China and the United States. Sanofi, Sandoz, Chemi, Rotexmedica GmbH, Baxter is the world's major downstream customer.
Global Heparin Sodium Market: Forecast by Region
Raw materials of heparin sodium are mainly fresh intestine, pancreatic enzymes, ion exchange resin and preservative etc. China pig slaughter amount accounted for more than 50% of the world. It has most abundant raw material resources all over the world. So, there are many manufacturers in China, such as Shenzhen Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Changzhou Qianhong Bio-pharma, Changshan Biochemical, Dongying Tiandong Pharmaceutical and Xinbai Pharmaceuticals etc. Shenzhen Hepalink is also a global leader in this industry. In the past decade, Shenzhen Hepalink has been expanding production facilities. SPL and Baxter are US market leaders. Bioibérica, Aspen Oss and Pharma Action are leaders in the European market.
In 2004, SPL expanded Changzhou's operations to produce heparin sodium, which required Baxter to file a manufacturing supplement with FDA to add the Chinese plant as an alternate API supplier. It was not until Jan. 2008, when FDA and Baxter started receiving hundreds of adverse event reports.The raw material for the recalled heparin batches was processed in China from pig's intestines by the American pharmaceutical firm Scientific Protein Laboratories. The U.S. Food and Drug Administration was quoted as stating that at least 81 deaths were believed to be linked to a raw heparin ingredient imported from the People's Republic of China, and that they had also received 785 reports of serious injuries associated with the drug’s use.
Upon investigation of these adverse events by the FDA, academic institutions, and the involved pharmaceutical companies, the contaminant was identified as an "over-sulfated" derivative of chondroitin sulfate, a closely related substance obtained from mammal or fish cartilage and often used as a treatment for arthritis. This event did not make SPL collapse, which greatly affected the pace of development of SPL. After the acquisition of SPL, Shenzhen Hepalink's sales increased by about 40% in 2014.
Global Heparin Sodium Market: Key Players
Shenzhen Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Changzhou Qianhong Bio-pharma, Changshan Biochemical, Dongying Tiandong Pharmaceutical, Xinbai Pharmaceuticals, SPL, Bioibérica, Baxter, Opocrin, Aspen Oss, Pharma Action and Pfizer, are the key vendors included in this report.
Would like to place an order or any question, please feel free to contact at firstname.lastname@example.org & Richard@amecoresearch.com
Contact No: +13474743864